Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Total Non-Current Liabilities (2016 - 2025)

Fortress Biotech (FBIO) has 13 years of Total Non-Current Liabilities data on record, last reported at $114.6 million in Q3 2025.

  • For Q3 2025, Total Non-Current Liabilities fell 16.99% year-over-year to $114.6 million; the TTM value through Sep 2025 reached $114.6 million, down 16.99%, while the annual FY2024 figure was $144.1 million, 12.15% down from the prior year.
  • Total Non-Current Liabilities reached $114.6 million in Q3 2025 per FBIO's latest filing, down from $120.8 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $242.4 million in Q4 2022 and bottomed at $114.6 million in Q3 2025.
  • Average Total Non-Current Liabilities over 5 years is $174.3 million, with a median of $165.6 million recorded in 2021.
  • Peak YoY movement for Total Non-Current Liabilities: skyrocketed 73.31% in 2021, then crashed 32.33% in 2023.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $168.6 million in 2021, then surged by 43.8% to $242.4 million in 2022, then plummeted by 32.33% to $164.0 million in 2023, then decreased by 12.15% to $144.1 million in 2024, then dropped by 20.47% to $114.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $114.6 million in Q3 2025, $120.8 million in Q2 2025, and $143.9 million in Q1 2025.